AR 101 - Arava

Drug Profile

AR 101 - Arava

Alternative Names: AR-101 - Arava; AR/101

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Arava Bio Tech
  • Developer Arava Bio Tech; Cato Research
  • Class Skin disorder therapies
  • Mechanism of Action Epithelial cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Wounds

Most Recent Events

  • 22 Jul 2016 Arava plans a phase II trial for Wounds in Israel (NCT02839226)
  • 10 Nov 2015 Phase-I/II clinical trials in Wounds (In volunteers) in USA (Topical) (NCT02602184)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top